A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment

NCT04656184 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Kawasaki Disease

Interventions

DRUG: ANAKINRA
DRUG: Intravenous immunoglobulin

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]